Sign In
Buy VYGR
$3.24
-0.200 (-5.81%)
At Close: Jul 13, 2026
- Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveragi
Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime' to Make Money
09:33am, Thursday, 02'nd Jul 2026
On the June 30 episode of Mad Money, a 23-year-old caller named Jackson from Iowa asked Jim Cramer about Voyager Therapeutics (NASDAQ:VYGR), a clinical-stage gene therapy company he wanted to hold for
LEXINGTON, Mass. , June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced
LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced
UNLOCKING SPACE: Elon Musk is BREAKING RECORDS for orbital launches
01:15pm, Friday, 12'th Jun 2026
Voyager Technologies Chairman and CEO Dylan Taylor joins ‘Mornings with Maria' to discuss SpaceX's record-breaking IPO, the rise of the space economy and Voyager's first year as a public company. #f
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
04:01pm, Thursday, 11'th Jun 2026
LEXINGTON, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced
- Dosing of adults with early Alzheimer's disease in clinical trial expected H2 2026 - - Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 - - VY1706 uses
- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager's continued innovation in gene therapy - LEXINGTON, Mas
Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates
07:01pm, Thursday, 07'th May 2026
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.53 per share a year ago.
Voyager Reports First Quarter 2026 Financial and Operating Results
04:01pm, Thursday, 07'th May 2026
- VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 - - Multiple presentations at ASGCT 2026, including late breaker on VY1706 3-month GLP tox data - - Ende
- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month GLP toxicology study in NHPs -
Reviewing Longeveron (NASDAQ:LGVN) & Voyager Therapeutics (NASDAQ:VYGR)
01:09am, Tuesday, 14'th Apr 2026
Longeveron (NASDAQ: LGVN - Get Free Report) and Voyager Therapeutics (NASDAQ: VYGR - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two bus
Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026
03:28am, Monday, 13'th Apr 2026
Voyager Therapeutics maintains a "Strong Buy" rating as it approaches a pivotal 2026 catalyst with tau PET imaging data from its phase 1b study in Alzheimer's disease. Company's anti-tau monoclonal an
Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript
02:12am, Monday, 23'rd Mar 2026
Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript
Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates
06:15pm, Monday, 09'th Mar 2026
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.59 per share a year ago.
